Adial Pharmaceuticals Files Patent to Extend Core Technology IP to 2044

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced the submission of a new patent application for its leading investigational drug, AD04. This therapeutic agent, a serotonin-3 receptor antagonist, is targeted at treating Alcohol Use Disorder (AUD) in heavy drinking patients. The patent, once granted, is expected to safeguard Adial's core assets until at least 2044.

Cary Claiborne, President and CEO of Adial, stated that the new patent application is a strategic move to extend the protection of the company's core assets, coinciding with the progress of their pharmacokinetics study for AD04. The application results from a comprehensive review of data and information following the recruitment of new patent counsel to enhance the company’s intellectual property portfolio.

Adial Pharmaceuticals specializes in developing treatments for addiction and related disorders. Their primary investigational drug, AD04, is designed for patients with a genetic predisposition to AUD. This drug was recently evaluated in the ONWARD™ pivotal Phase 3 clinical trial, which aimed to treat AUD in subjects identified through a companion diagnostic genetic test developed by the company. The ONWARD trial demonstrated promising outcomes in reducing alcohol consumption in heavy drinking patients, with no significant safety or tolerability issues.

Beyond AUD, AD04 is believed to have potential applications in treating other addictive disorders, including Opioid Use Disorder, gambling addiction, and obesity. This potential broadens the scope of AD04, positioning it as a versatile therapeutic agent in the field of addiction treatment.

The recent patent application is a pivotal step for Adial, as it seeks to solidify its market position and extend the commercial viability of its innovations. By anticipating the patent to be in effect until at least 2044, Adial aims to maintain a competitive edge in the biopharmaceutical industry, particularly in addiction treatment.

Adial’s approach leverages genetic targeting, which may enhance the effectiveness of AD04 in individuals genetically predisposed to AUD. This strategy not only personalizes treatment but also maximizes therapeutic outcomes, aligning with modern trends in precision medicine.

The company's focus remains on advancing their AD04 program, continuing research and development, and exploring potential partnerships and collaborations to enhance their market reach and development capabilities. Adial is committed to addressing the significant unmet needs in addiction treatment, contributing to improved health outcomes and quality of life for individuals struggling with these disorders.

In summary, Adial Pharmaceuticals' latest patent application for AD04 represents a significant milestone in their ongoing efforts to develop effective treatments for addiction. With the anticipated patent protection extending to at least 2044, Adial is well-positioned to continue its innovative work in the biopharmaceutical sector, offering hope and new therapeutic options for patients with AUD and other addictive disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!